Меню
Идёт набор NCT06624462

Effectiveness of a Pragmatic, Metabolic Care Clinic for Patients With Severe Mental Illness - The Meta Care Clinic

Без фазы С лечением Severe Mental Disorder Metabolic Complication Side-Effect;Medication Schizophrenia Spectrum and Other Psychotic Disorders

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Treatment in the Meta Care Clinic, Standard care with general practitioner and/or outpatient clinics.
Кому может быть актуально
Состояния в реестре: Severe Mental Disorder, Metabolic Complication, Side-Effect;Medication, Schizophrenia Spectrum and Other Psychotic Disorders. Базовые параметры: 18 лет — 45 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Дания
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Обзор

This study will examine the effectiveness of a Pragmatic, Metabolic Care Clinic for Patients With Severe Mental Illness

Подробное описание

Severe mental illness (SMI), including schizophrenia spectrum disorders and bipolar disorder, is associated with high mortality rates and cardiovascular disease. Obesity and dysmetabolism caused by antipsychotic medication comprise modifiable risk factors, which remain undertreated.

The investigators will address the gaps in cardiometabolic care of SMI patients by examining the effectiveness of a pragmatic metabolic care clinic for patients with SMI. Moreover, the investigators will include qualitative investigation of patients' perspectives in relation to acceptability, satisfaction with care, and motivation for health behaviour change.

A total of 84 patients between 18-45 years with diagnoses of schizophrenia spectrum disorders or bipolar disorder will be recruited from inpatient and outpatient clinics in the Mental Health Services of the Capital Region of Denmark. Eligible patients are antipsychotics-treated and present with a 5% weight increase / 5 cm waistline increase since initiation of antipsychotic therapy or body mass index (BMI) ≥30 kg/m2 or BMI ≥27 kg/m2 and concomitant prediabetes, diabetes, hypertension, sleep apnoea and/or dyslipidaemia.

Patients will be enrolled in an open-label randomized controlled parallel-group trial with an allocation-ratio of 1:1 to a pragmatic, specialized metabolic clinic with measurement-based care and evidence-based best-practice treatment or standard care. The primary outcome is the proportion of patients in the intervention group achieving a weight loss ≥5% of initial body weight vs the standard care group at 12 months. Secondary and exploratory outcomes include changes in other cardiovascular risk factors, quality of life, personal recovery and cognitive measures. Finally, qualitative interviews will explore patient experience and contextual factors.

Вмешательства

  • Другое Treatment in the Meta Care Clinic
    * Consultations by medical doctors with specific metabolic training from the metabolic clinic located at Centre for Addiction and Mental Health in Toronto, Canada, and an exercise physiologist. * Evaluation of their psychopharmacotherapy with consultation and detailed recommendations to the patients' treating psychiatrist and/or general practitioner regarding dosage reductions or switching of psychotropics if this is clinically feasible to reduce the metabolic burden. * Lifestyle interventions *
  • Другое Standard care with general practitioner and/or outpatient clinics
    Following measurements after 12 months, patients will receive individualized lifestyle recommendations from an exercise physiologist and a MD will offer to send recommendations regarding the following potential post-trial interventions to the patients' general practitioner and/or outpatient clinic prepared in close collaboration with recognized specialists in psychiatry and endocrinology: * Suggestions regarding relevant psychotropic medication adjustments or switches if this is found relevant

Первичные конечные точки

  • Proportion of patients achieving a weight loss of ≥5% of initial body weight. [Срок оценки: 12 months]
Вторичные конечные точки (12)
  • The metabolic composite score [Срок оценки: 12 months]
  • Cardiovascular risk factors [Срок оценки: 12 months]
  • Proportion of patients achieving a weight loss of ≥10% of initial body weight. [Срок оценки: 12 months]
  • Proportion of patients achieving a ≥50% reduction of low-density lipoprotein cholesterol [Срок оценки: 12 months]
  • Body weight [Срок оценки: 12 months]
  • Waist circumference [Срок оценки: 12 months]
  • Body mass index [Срок оценки: 12 months]
  • Glucose [Срок оценки: 12 months]
  • Insulin [Срок оценки: 12 months]
  • The homeostatic Model Assessment for Insulin Resistance [Срок оценки: 12 months]
  • Total cholesterol [Срок оценки: 12 months]
  • Low-density lipoprotein cholesterol [Срок оценки: 12 months]

Критерии участия

Критерии включения

  • Patients with schizophrenia spectrum disorders (International classification of diseases; ICD-10: DF2x) or bipolar disorder (ICD-10: DF30.x or DF31.x)
  • Medical treatment with antipsychotics
  • Age 18-45 years
  • Legally competent
  • Able to give informed consent

and either:

\- Body mass index (BMI) ≥30 kg/m2.

Or

  • BMI ≥27 kg/m2 and at least one of the following:
  • Hypertension defined as treatment with ≥1 antihypertensive drug or out-of-office / 24-hour, non-invasive ambulatory blood pressure ≥140/90 mmHg within the previous 6 months
  • Dyslipidaemia defined as treatment with ≥1 lipid-lowering drug or elevated low-density lipoprotein (LDL) cholesterol (≥3.0 mmol/l), elevated triglycerides (≥1.7 mmol/l) or low high-density lipoprotein cholesterol (≥1.2 mmol/l in women and ≥1.0 mmol/l in men) within the previous 6 months
  • Sleep apnoea (ICD-10 DG473).
  • Prediabetes or diabetes defined as HbA1c ≥42 mmol/mol or impaired fasting glucose as defined by the International Diabetes Federation within the previous 6 months.

Or

\- a history of rapid weight gain during antipsychotic therapy defined as increases of either ≥5% body weight or ≥5 cm waist circumference since initiation of antipsychotic therapy.

Критерии исключения

  • Clinical or laboratory evidence of comorbid medical disease not compatible with participation as judged by the research team.
  • Unstable psychiatric disorder as judged by the research team.
  • Severe current drug or alcohol misuse as judged by the research team.
  • Acute suicidal risk.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Открытое
Основная цель
Лечение

Центры проведения

Дания · 1 центр
  • Centre for Neuropsychiatric Schizophrenia Research, CNSR, Mental Health Centre Glostrup — Glostrup Municipality

Идентификаторы

NCT: NCT06624462 · The Meta Care Clinic · H-23045618 · p-2023-14342 · 2096-00099B

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗